Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$88.41 USD

88.41
41,963,872

-0.09 (-0.10%)

Updated Jun 18, 2026 04:03 PM ET

After-Market: $88.30 -0.11 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PBH or ABT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBH vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

PBH vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBH vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

Abbott (ABT) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.

Moumi Mondal headshot

Hologic Trading Near 52-Week High: How Should You Play the Stock?

by Moumi Mondal

HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.

Zacks Equity Research

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moumi Mondal headshot

Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth

by Moumi Mondal

HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.

Moumi Mondal headshot

How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?

by Moumi Mondal

BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.

Zacks Equity Research

Abbott Stock May Benefit Following Volt PFA's FDA Approval

by Zacks Equity Research

ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.

Moumi Mondal headshot

Should You Hold On To BSX Stock Despite Its Premium Valuation?

by Moumi Mondal

Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks.

Aparajita Dutta headshot

Pharma's $370B Bet on America: The ETF Plays for 2026

by Aparajita Dutta

Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.